Conference Events

ENDO 2019 is jam-packed with sessions to keep you up-to-date with clinical and scientific advances in endocrinology; and thanks to the Endocrine Society’s Continuing Medical Education Services (CMES) and Special Programs Committee (SPC) there are even more opportunities to hear from the experts with Conference Events.

Conference Events are certified by the Endocrine Society and are planned and conducted under the supervision of the SPC in strict compliance with the Essential Standards & Guidelines of the Accreditation Council for Continuing Medical Education (ACCME).

There is no cost to attend and all ENDO 2019 attendees are welcome; however, seating is limited and advance registration is recommended. Complimentary breakfast or dinner will be provided. Tickets will not be issued this year, so arrive early as seating is done on a first-come, first-served basis. While available seating cannot be guaranteed, we will make every effort to accommodate you.

Register for Conference Events when you register for ENDO 2019 or add an event to an existing ENDO registration.

Saturday, March 23, 2019

Lilly Diabetes Educational Exchange (5:30 PM–7:15 PM)
Great Hall, Ernest N. Morial Convention Center

We have partnered with Lilly Diabetes to bring you an educational evening that will take you through the latest developments in diabetes care. As part of the program, you will engage with interactive stations, hear your colleagues' viewpoints on relevant topics impacting your clinical practice, and meet the dedicated Lilly Diabetes team. Food and refreshments will be provided for attendees. RSVP today.

 

Patient-Centered Approaches to Long-Term Success in Weight Loss (7:00 PM–9:15 PM)
Program Chair: W. Troy Donahoo, MD—University of Florida
CME/MOC: 2.00

Learning Objectives—Upon completing this activity, learners will better be able to:

  • Recognize obesity as a disease and assess patients for obesity and its comorbidities
  • Apply evidence-based guidelines in the selection and use of pharmacotherapy to treat patients with obesity
  • Assess patient-centered strategies to overcome challenges in long-term successful weight loss maintenance with lifestyle interventions.

The Endocrine Society thanks Novo Nordisk for supporting this program.


A Patient Centered Approach to Hypophosphatemia: Diagnosis, Evaluation, and Treatment (7:00 PM–9:15 PM)
Program Chair: Anda Raluca Gonciulea, MD—Yale New Haven Northeast Medical Group
CME/MOC: 2.00

Learning Objectives—Upon completing this activity, learners will be able to:

  • Incorporate best practices for evaluating and diagnosing patients with hypophosphatemia in their practice
  • Discuss pathophysiology and treatment strategies for patients with FGF-23 mediated phosphate disorders
  • Discuss pathophysiology and treatment strategies for patients with non-FGF-23 mediated phosphate disorders

The Endocrine Society thanks Ultragenyx Pharmaceutical for supporting this program.


Sunday, March 24, 2019

Breakfast
New Medical Options for the Treatment of Advanced Thyroid Cancer (5:30 AM–7:45 AM)
Program Chair: Steven I Sherman MD- MD Anderson Cancer Center
CME/MOC: 2.00

Learning Objectives—Upon completing this activity, learners will better be able to:

  • Summarize the importance of mutation-directed targeted therapies for thyroid cancers
  • Incorporate tumor genotype information when selecting targeted therapy
  • Consider updated clinical trial information on emerging and currently approved therapies for advanced thyroid cancers
  • Apply multiple interventional techniques for the treatment of locally advanced disease

The Endocrine Society thanks Eisai Co. and Bayer Healthcare Pharmaceuticals LLC for supporting this program.


Breakfast
Updates in Individualizing Therapy in Type 2 Diabetes: Optimizing Insulin and Non-Insulin Combinations (5:30 AM–7:45 AM)
Program Chair: Carol H. Wysham, MD, MultiCare Rockwood Clinic Diabetes & Endocrinology Center
CME/MOC: 2.00

Learning Objectives—Upon completing this activity, learners will better be able to:

  • Compare and contrast the therapeutic characteristics, efficacy, and safety of ultra-long-acting basal insulins and faster-acting prandial insulins
  • Incorporate the emerging evidence into practice regarding combination of GLP-1 agonists and SGLT-2 inhibitors with other non-insulin diabetes therapies in treatment of type 2 diabetes
  • Address highly insulin resistant patients using concentrated insulins and combination therapies
  • Devise individualized treatment strategies for insulin and non-insulin diabetes therapies using current guidelines and up-to-date trial information

The Endocrine Society thanks Eli Lilly and Company Pharmaceutical for supporting this program.


Clinical Advances in Adult Growth Hormone Deficiency: Delivering Patient-Centered Care to Improve Outcomes (5:45 PM–8:15 PM)
Program Chair: Beverly MK Biller, MD—Harvard Medical School
Managed by: ASiM CE, LLC
CME/MOC: 2.00

Learning Objectives—Upon completing this activity, learners will better be able to:

  • Identify key clinical components, including recent advances, that inform the differential diagnosis of GHD in adult patients
  • Evaluate the clinical necessity, efficacy, and safety of rhGH therapy as a treatment strategy for adult GHD
  • Recommend individualized dosing and monitoring strategies for adults using growth hormone therapy
  • Incorporate practical strategies to address barriers to rhGH therapy adherence and improve the delivery of patient centered-care for adult patients with GHD

The Endocrine Society thanks Novo Nordisk for supporting this program.


Unraveling the Genetics of Rare Causes of Obesity: Emerging Options Across the Lifespan (5:45 PM–8:15 PM)
Program Chair: Jennifer Lynne Miller, MD—University of Florida
This program is a non-CME program. Participants will not receive CME credit for attending.

Program Summary—Obesity is a complex disease that affects individuals differently with contributing factors well beyond lifestyle and environment. Among these factors, the role of genetics in obesity is often overlooked or misunderstood. In relatively recent years, the field of obesity medicine has uncovered genetic causes of obesity and developed novel treatments as emerging therapies. Although we are at the cusp of new options for rare causes of obesity, there are persistent challenges in awareness, screening, limited treatment options, and limited referral networks. This program will update clinicians on genetic causes of obesity and discuss how emerging treatments are shaping the landscape of options.

The Endocrine Society thanks Rhythm Pharmaceuticals for supporting this program.


The Next Generation of CGM: How Flash Glucose Monitoring is Revolutionizing Diabetes Management (5:45 PM–8:15 PM)
Program Chair: Yogish C. Kudva, MBBS—Mayo Clinic-Rochester
This program is a non-CME program. Participants will not receive CME credit for attending.

Program Summary—Advances in continuous glucose monitoring (CGM) are changing glucose management from a largely reactionary approach to one that is predictive in nature. Flash glucose monitoring is part of this revolution. How we leverage these new tools in practice will depend of providers’ understanding of newer technology and their ability to effectively communicate practical guides to their patients. This program will update clinicians on how flash glucose monitoring is changing the landscape and how clinicians how put practical guides into action to make the most newer technologies.

The Endocrine Society thanks Abbott Diabetes Care for supporting this program.


Monday, March 25, 2019

Hypoparathyroidism in Clinical Practice: Improving Patient Outcomes for Better Quality of Life (5:45 PM–8:15 PM)
Program Chair: Dolores Shoback, MD—University of California San Francisco
Managed by: Medscape
CME/MOC: 2.00

Learning Objectives

  • Increased knowledge regarding:
    • Challenges faced by endocrinologists related to diagnosis and management of hypoparathyroidism
    • New data related to safety, efficacy, and impact on quality of life of pharmacotherapy options for hypoparathyroidism
  • Greater competence related to
    • Early recognition and diagnosis of hypoparathyroidism
    • Safe and effective management of hypoparathyroidism in acute and chronic settings
  • Improvement of QOL for patients with hypoparathyroidism

The Endocrine Society thanks Shire for supporting this program.


Meeting the Needs of Patients, Not LDL-C Goals: The Role of PCSK9 Inhibitors (5:45 PM–8:15 PM)
Program Chair: Sergio Fazio, MD, PhD—Oregon Health & Science University
CME/MOC: 2.00

Learning Objectives—Upon completing this activity, learners will better be able to:

  • Summarize the biology and genetic underpinnings of dyslipidemia as related to the LDL receptor.
  • Discuss and identify lipid lowering therapies beyond traditional therapeutics like statins.
  • Recognize the benefit of including PCSK9 inhibitors in the treatment of patients with ASCVD or FH.
  • Assess the clinical trial evidence for the efficacy and safety of PCSK9 inhibitors in patients with statin intolerance.
  • Review the cardiovascular risk reduction provided by PCSK9 inhibitors in combination with statin therapy.

The Endocrine Society thanks Amgen Inc for supporting this program